| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 536170100 | Boron, phosphorus, heavy metal or aluminum containing | 27 |
| 20090312531 | OLIGNUCLEOTIDES COMPRISING A LIGAND TETHERED TO A MODIFIED OR NON-NATURAL NUCLEOBASE - One aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one ligand tethered to an altered or non-natural nucleobase. In certain embodiments, the non-natural nucleobase is difluorotolyl, nitropyrrolyl, or nitroimidazolyl. In certain embodiments, the ligand is a steroid or aromatic compound. In certain embodiments, only one of the two oligonucleotide strands comprising the double-stranded oligonucleotide contains a ligand tethered to an altered or non-natural nucleobase. In certain embodiments, both of the oligonucleotide strands comprising the double-stranded oligonucleotide independently contain a ligand tethered to an altered or non-natural nucleobase. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one ligand tethered to an altered or non-natural nucleobase. In certain embodiments, the non-natural nucleobase is difluorotolyl, nitropyrrolyl, or nitroimidazolyl. In certain embodiments, the ligand is a steroid or aromatic compound. In certain embodiments, the ribose sugar moiety that occurs naturally in nucleosides is replaced with a hexose sugar, polycyclic heteroalkyl ring, or cyclohexenyl group. In certain embodiments, at least one phosphate linkage in the oligonucleotide has been replaced with a phosphorothioate linkage. | 12-17-2009 |
| 20100076183 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS - A nucleoside monomer that is protected by a thionocarbamate protecting group is provided, as well as a method for making a polynucleotide that uses the same. Also provided is a polynucleotide synthesis method that employs a diamine to deprotect a protected polynucleotide. | 03-25-2010 |
| 20100152429 | SODIUM SALT OF DISACCHARIDE COMPOUND, METHOD FOR PRODUCING THE SAME, AND USE OF THE SAME - Disclosed are a sodium salt represented by the average formula (I) below, and a method for producing such a sodium salt. (In the formula, m | 06-17-2010 |
| 20110137019 | NUCLEIC ACID COMPRISING ZWITTERIONIC NUCLEOTIDES - This invention provides pH-responsive zwitterionic nucleotides and nucleic acids comprising said nucleotides, wherein said zwitterions are constituted from one or more anionic internucleoside linkages and one or more cationic moieties and said zwitterionic nucleotides further comprise either one or more hydrophobic moieties or one or more TEE's with the general structure (I) Hydrophobic element-pH-responsive hydrophilic elements (I). | 06-09-2011 |
| 20110152508 | REAGENTS AND METHODS FOR PREPARING LPS ANTAGONIST B1287 AND STEREOISOMERS THEREOF - The present invention provides methods for preparing LPS antagonist lipodisaccharide B1287 and stereoisomers thereof, which compounds are useful as in the prophylactic and affirmative treatment of endotoxemia including sepsis, septicemia and various forms of septic shock. Also provided are synthetic intermediates useful for implementing the inventive methods. | 06-23-2011 |
| 20110213134 | Synthetic membrane anchors - The invention relates to synthetic molecules that spontaneously and stably incorporate into lipid by-layers, including cell membranes. Particularly, although not exclusively, the invention relates to the use of these molecules as synthetic membrane anchors or synthetic molecule constructs to effect qualitative and quantitative changes in the expression of cell surface antigens. | 09-01-2011 |
| 20120095196 | POLYHEDRALTRANSITION METAL COMPLEX, TRANSITION METAL COMPLEX CONTAINING ULTRAFINE PARTICLES THEREIN, AND PROCESS FOR PRODUCING SAME - Provided is a polyhedral transition metal complex including a hollow shell, the hollow shell including n1 (where n1 is an integer from 6 to 60) transition metal atoms and 2(n1) bidentate organic ligands, the bidentate organic ligands including a group derived from a polyhydroxy compound via a linking group, and formed so that the group derived from the polyhydroxy compound is oriented toward an inner space of the hollow shell. Also provided are: an ultrafine particle-containing transition metal complex including the polyhedral transition metal complex, and ultrafine particles of a metal oxide, the ultrafine particles being included within the hollow shell of the polyhedral transition metal complex; a method of producing the same. The invention thus provides a polyhedral transition metal complex that makes it possible to efficiently produce metal oxide particles having a uniform particle size of several nanometers, an ultrafine particle-containing polyhedral transition metal complex in which metal oxide particles are included within a polyhedral structure and the method of producing the same. | 04-19-2012 |
| 20120232256 | PROCESS FOR PRODUCING 1,2-TRANS-GLYCOSIDE COMPOUND - In preparing a glycoside compound from (a) a furanose compound or pyranose compound, and (b) an alcohol compound, a process for preparing a glycoside compound in which glycosidic bond locates selectively trans form relative to C-2 hydroxyl group, the process comprising using a furanose compound wherein the hydroxyl at the 2-position may have a substituent protected with a group A, or a pyranose compound which may have a substituent | 09-13-2012 |
| 20120277416 | CELL SURFACE COATING WITH HYALURONIC ACID OLIGOMER DERIVATIVE - A method of localising reproduction assisting hyaluronic acid to reproductive cell surfaces by covalently linking it to lipids is disclosed. | 11-01-2012 |
| 20130035479 | FUNCTIONALIZED BETA 1,6 GLUCOSAMINE DISACCHARIDES AND PROCESS FOR THEIR PREPARATION - The present invention relates to a novel process for the chemical synthesis of β-(1->6)-linked glucosamine disaccharides of the formula (1) and (intermediate) compounds relating to the process. According to further aspects the invention relates to compositions comprising the compounds and the use of the compounds in the synthesis of disaccharides and medicine. | 02-07-2013 |
| 20130178609 | MODULAR CONSTRUCTION OF LIPOPHOSPHOLIPIDS - The present invention relates to fluorescent and/or targeting lipophilic compounds having the general formula (R1O)(R2O)P(O)—R3-R4-R5 wherein R1 and R2 are each independently a linear or branched, saturated or unsaturated C2-C24 alkyl, or a linear or branched, saturated or unsaturated C2-C24 monoalkenyl or polyalkenyl, the polyalkenyl having from 2 to 4 double bonds, or a linear or branched, saturated or unsaturated C2-C24 monoalkinyl or polyalkinyl, the polyalkinyl having from 2 to 4 triple bonds; R3 is selected from 0, S, —C(R6)2-, —CH(R7)-, —C(S)—N(R6)-, —CH(SR7)-S—S— or —N(R6)- wherein R6 is a hydrogen atom or a C1-C4 alkyl, and R7 is a C1-C4 alkyl; R4 comprises at least one junction function and at least one linker; and R5 is at least one chemical fluorescent group or at least one targeting group. Methods for preparing said lipophilic compounds are also disclosed. | 07-11-2013 |
| 20130225798 | QUANTIFICATION METHOD FOR REMAINING LIVER FUNCTION AND NOVEL LIVER RECEPTOR IMAGING AGENT - A test indicator for quantifying remaining liver function is provided. A novel liver receptor imaging agent with liver targeting property is utilized to develop a method for quantifying remaining liver function to serve as test indicator for judging the liver failure outcome in clinic, particularly for judging the necessity of liver transplantation for patients with liver failure or liver disease. The radioactivity uptake of the test indicator was negatively correlated with the extent of liver reserve. The cutoff value of liver reserve for liver transplantation is also disclosed. | 08-29-2013 |
| 20140011987 | Synthetic Lipid A Derivative - The invention provides functionalized monosaccharides and disaccharides suitable for use in synthesizing a lipid A derivative, as well as methods for synthesizing and using a synthetic lipid A derivative. | 01-09-2014 |
| 20140046044 | NOVEL GLYCOSYL PHOSPHITES - The present invention relates to providing compounds of general formula 1 | 02-13-2014 |
| 20140243513 | Methods for the Production of 3-O-Deactivated-4'-Monophosphoryl Lipid A (3D-MLA) - Herein is disclosed a method for producing lipopolysaccharide (LPS), comprising: (a) growing a culture of a deep rough mutant bacterial strain in a medium; (b) maintaining the culture in stationary phase for at least about 5 hr; (c) harvesting, cells from the culture; and (d) extracting LPS from the cells. The method allows for the production of an LPS which can be used to produce a 3-O-deacylated monophosphoryl lipid A (3D-MLA) having at least about 20 mol % of the hexaacyl congener group. | 08-28-2014 |
| 20140275502 | PROCESS FOR THE PREPARATION OF CERTAIN TRIARYL RHAMNOSE CARBAMATES - Aryl boronic esters and boronic acids containing the rhamnose carbamate moiety are coupled to a triazole with an appropriate leaving group, generating a 4-triazolylphenyl carbamate in good yield and without cleavage of the carbamate linkage. | 09-18-2014 |
| 20140275503 | PROCESS FOR THE PREPARATION OF CERTAIN TRIARYL RHAMNOSE CARBAMATES - Aryl boronic esters and boronic acids containing the rhamnose carbamate moiety are prepared by coupling a boronate substituted phenyl isocyanate with a tetrahydropyran-2-ol in the presence of cesium carbonate. | 09-18-2014 |
| 20140275504 | PROCESS FOR THE PREPARATION OF CERTAIN TRIARYL RHAMNOSE CARBAMATES - Aryl boronic esters containing the rhamnose carbamate moiety are prepared in good yield and without cleavage of the carbamate linkage by first contacting p-bromophenyl isocyanate with a tetrahydropyran-2-ol followed by reaction with a diboron compound. | 09-18-2014 |
| 20140371437 | CELL SURFACE COATING WITH HYALURONIC ACID OLIGOMER DERIVATIVE - A method of localizing reproduction assisting hyaluronic acid to reproductive cell surfaces by covalently linking it to lipids is disclosed. | 12-18-2014 |
| 20150011740 | FLUORINE-CONTAINING WATER SOLUBLE PLATINUM COMPLEXES FOR TUMOR TREATMENT AND PROCESS OF PREPARING SAME - Disclosed are fluorine-containing highly water-soluble platinum complexes for tumor treatment and preparation method, said platinum complexes being shown as formula (I); The present fluorine-containing platinum complexes exhibiting superior cytotoxicity and efficacy compare to the clinical drug oxaliplatin, the design strategy of the present platinum complexes is to enhance the solubility and stability favor its clinical use. | 01-08-2015 |
| 20150126718 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE - Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine. | 05-07-2015 |
| 20150126719 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION - Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein C-III (ApoCIII). In certain embodiments, the ApoCIII targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting ApoCIII for use in decreasing ApoCIII to treat, prevent, or ameliorate diseases, disorders or conditions related to ApoCIII. Certain diseases, disorders or conditions related to ApoCIII include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof. | 05-07-2015 |
| 20150126720 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION - Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)]. In certain embodiments, the apo(a) targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting apo(a) for use in decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) and/or Lp(a). Certain diseases, disorders or conditions related to apo(a) and/or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof. | 05-07-2015 |
| 20150141630 | PROCESS FOR PREPARATION OF IRON SUCROSE - The present invention is directed to processes for preparation of iron sucrose complex and purification of the obtained iron sucrose through diafiltration. | 05-21-2015 |
| 20160009750 | PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | 01-14-2016 |
| 20160076030 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION - Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine. | 03-17-2016 |
| 20160083414 | PHOSPHORAMIDITE BUILDING BLOCKS FOR SUGAR-CONJUGATED OLIGONUCLEOTIDES - Novel nucleoside phosphoramidite building blocks for preparation of synthetic oligonucleotides containing at least one phosphotriester linkage conjugated to a monosaccharide and synthetic processes for making the same are disclosed. Furthermore, oligomeric compounds are prepared using said building blocks, preferably followed by removal of protecting groups to provide monosaccharide-conjugated oligonucleotides. | 03-24-2016 |
